SCHEMBL1877907

SCHEMBL1877907

O=C(Cc1ccc(F)cc1Cl)Nc1onc(-c2cccc(OCc3ccccc3)c2)c1-c1ccncn1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.65
MAPK9 P45984 1/20 0.57
MAPK10 P53779 1/20 0.57
MAPK11 Q15759 1/20 0.57
EGFR P00533 1/20 0.42
RAF1 P04049 1/20 0.42
CYP3A4 P08684 1/20 0.42
ARAF P10398 1/20 0.42
BRAF P15056 1/20 0.42
KDR P35968 1/20 0.42
MAP2K2 P36507 1/20 0.42
FLT3 P36888 1/20 0.42
KCNH2 Q12809 1/20 0.42
ERBB4 Q15303 1/20 0.42
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
GPR34 Q9UPC5 1/20 0.37
PPARD Q03181 1/20 0.37
NR1H4 Q96RI1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1875210 0.93 MAPK14 (0.64) MAPK14MAPK9MAPK10MAPK11EGFR
SCHEMBL1879489 0.88 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11EGFR
SCHEMBL1875081 0.88 MAPK14 (0.68) MAPK14MAPK9MAPK10MAPK11EGFR
SCHEMBL1874208 0.85 MAPK14 (0.81) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1880210 0.85 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1873703 0.84 MAPK14 (0.83) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1875712 0.83 MAPK14 (0.82) MAPK14MAPK9MAPK10MAPK11CYP3A4
SCHEMBL1876787 0.83 MAPK14 (0.77) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1876167 0.82 MAPK14 (0.81) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1875074 0.81 MAPK14 (0.80) MAPK14MAPK9MAPK10MAPK11CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.